E3508: A phase II randomized trial of carboplatin (C), paclitaxel (P), and bevacizumab (B) with or without IMC-A12 (cixutumumab) in patients with advanced nonsquamous, non-small cell lung cancer (NSCLC).

被引：1
|
作者：
Argiris, A.
Lee, J.
Schiller, J. H.
机构：
[1] Univ Pittsburgh, Pittsburgh, PA USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.tps221
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS221
引用
收藏
页数：1
相关论文
共 50 条
  • [1] E3508: Randomized trial of carboplatin (C), paclitaxel (P), bevacizumab (B) with or without cixutumumab (Cx) in patients (pts) with advanced non-squamous, non-small cell lung cancer (NSCLC).
    Argiris, Athanassios
    Lee, Ju-Whei
    Stevenson, James
    Sulecki, Matthew Gerard
    Hugec, Vladimir
    Choong, Nicholas W.
    Saltzman, Joel N.
    Song, Wei
    Hansen, Richard M.
    Evans, Tracey L.
    Ramalingam, Suresh S.
    Schiller, Joan H.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] Phase II randomized trial of carboplatin, paclitaxel, bevacizumab with or without cixutumumab (IMC-A12) in patients with advanced non-squamous, non-small-cell lung cancer: a trial of the ECOG-ACRIN Cancer Research Group (E3508)
    Argiris, A.
    Lee, J. W.
    Stevenson, J.
    Sulecki, M. G.
    Hugec, V.
    Choong, N. W.
    Saltzman, J. N.
    Song, W.
    Hansen, R. M.
    Evans, T. L.
    Ramalingam, S. S.
    Schiller, J. H.
    ANNALS OF ONCOLOGY, 2017, 28 (12) : 3037 - 3043
  • [3] Safety analysis of a phase II randomized trial of carboplatin (C), paclitaxel (P), bevacizumab (B) with or without cixutumumab (CX) in patients (pis) with advanced nonsquamous, non-small cell lung cancer (NSCLC).
    Argiris, Athanassios
    Lee, Ju-Whei
    Leach, Joseph W.
    Schiller, Joan H.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [4] Randomized, open-label phase II study of motesanib or bevacizumab in combination with paclitaxel and carboplatin (P/C) for advanced nonsquamous non-small cell lung cancer (NSCLC)
    Blumenschein, G. R.
    Kabbinavar, F. F.
    Menon, H.
    Mok, T.
    Stephenson, J.
    Beck, J. T.
    Lakshmaiah, K.
    Kracht, K.
    Sikorski, R. S.
    Schwartzberg, L. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First -Line Therapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer
    Novell, Silvia
    Scagliotti, Giorgio
    de Castro, Gilberto, Jr.
    Kiyik, Murat
    Kowalyszyn, Ruben
    Deppermann, Karl-Matthias
    Arriola, Edurne
    Bosquee, Lionel
    Novosiadly, Ruslan D.
    Nguyen, Tuan S.
    Forest, Amelie
    Tang, Shande
    Kambhampati, Siva Rama Prasad
    Cosaert, Jan
    Reck, Martin
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (02) : 383 - 389
  • [6] AN OPEN-LABEL, MULTICENTER, RANDOMIZED, PHASE II STUDY OF CISPLATIN AND PEMETREXED WITH OR WITHOUT CIXUTUMUMAB (IMC-A12) AS FIRST-LINE THERAPY IN PATIENTS WITH ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER
    Scagliotti, Giorgio
    Castro, Gilberto, Jr.
    Kiyik, Murat
    Ruben, Kowalyszyn
    Deppermann, Karl-Matthias
    Arriola, Edurne
    Bosquee, Lionel
    Willey, Richard G.
    Cosaert, Jan
    Reck, Martin
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S601 - S601
  • [7] A randomized phase II study of paclitaxel (P) and carboplatin (C) ± bevacizumab (B) ± dulanermin (D) in non-small lung cancer (NSCLC)
    Blackhall, F. H.
    Mark, Z.
    Zatloukal, P.
    Szima, B.
    Albert, I.
    Juhasz, E.
    Yang, X.
    Smethurst, D.
    Hei, Y.
    Soria, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [8] A phase II trial of first-line bevacizumab in combination with pemetrexed and carboplatin in advanced nonsquamous non-small cell lung cancer (NSCLC)
    Skaff, Z. G.
    Hageboutros, A.
    Krieger, K.
    Coakley, S.
    Somer, R.
    Stevenson, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [9] A phase II trial of weekly paclitaxel and carboplatin for elderly patients with advanced non-small cell lung cancer (NSCLC).
    Usui, K
    Inoue, A
    Ishimoto, O
    Tanaka, M
    Koinumaru, S
    Matsubara, N
    Kanbe, M
    Gomi, K
    Saijo, Y
    Nukiwa, T
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 682S - 682S
  • [10] Phase I dose-escalation study of sorafenib in combination with bevacizumab (B), paclitaxel (P), and carboplatin (C) for the treatment of advanced nonsquamous non-small cell lung cancer (NSCLC).
    Blumenschein, G. R.
    Molina, J. R.
    Lathia, C. D.
    Ong, T. J.
    Roth, D.
    Rajagopalan, P.
    Fossella, F. V.
    Kies, M. S.
    Marks, R. S.
    Adjei, A. A.
    Sundaresan, P. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345